Last reviewed · How we verify

NCT03285230: E3N

The French E3N Prospective Cohort Study

Status unknown Last updated 19 September 2017
What this trial tests

trial in Breast Cancer in 100,000 participants. Status unknown.

Timeline
15 June 1990
Primary endpoint
15 November 1991
15 December 2025

Quick facts

Lead sponsorInstitut National de la Santé Et de la Recherche Médicale, France
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment100,000
Start date15 June 1990
Primary completion15 November 1991
Estimated completion15 December 2025

Conditions studied

Sponsor

Institut National de la Santé Et de la Recherche Médicale, France — full company profile →

Who can join

40 and older, female only, with Breast Cancer or Colo-rectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The French E3N cohort was initiated in 1990 to investigate the risk factors associated with cancer and other major non-communicable diseases in women. The participants were insured through a national health system that primarily covered teachers, and were enrolled from 1990 after returning baseline self-administered questionnaires and providing informed consent. The cohort comprised nearly 100 000 women with baseline ages ranging from 40 to 65 years. Follow-up questionnaires were sent approximately every 2-3 years after the baseline and addressed general and lifestyle characteristics together with medical events (cancer, cardiovascular diseases, diabetes, depression, fractures and asthma, among others). The follow-up questionnaire response rate remained stable at approximately 80%. A biological material bank was generated and included blood samples collected from 25 000 women and saliva samples from an additional 47 000 women. Ageing among the E3N cohort provided the opportunity to investigate factors related to agerelated diseases and conditions as well as disease survival.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Associations Between Migraine and Type 2 Diabetes in Women: Findings From the E3N Cohort Study.
    Fagherazzi G, El Fatouhi D, Fournier A, Gusto G, et al · · 2019 · cited 44× · PMID 30556831 · DOI 10.1001/jamaneurol.2018.3960
  2. BMI in the Associations of Plant-Based Diets with Type 2 Diabetes and Hypertension Risks in Women: The E3N Prospective Cohort Study.
    Laouali N, Shah S, MacDonald CJ, Mahamat-Saleh Y, et al · · 2021 · cited 26× · PMID 34236437 · DOI 10.1093/jn/nxab158
  3. Circulating inflammatory biomarkers, adipokines and breast cancer risk-a case-control study nested within the EPIC cohort.
    Cairat M, Rinaldi S, Navionis AS, Romieu I, et al · · 2022 · cited 21× · PMID 35430795 · DOI 10.1186/s12916-022-02319-y
  4. Reproductive characteristics, use of exogenous hormones and Parkinson disease in women from the E3N study.
    Pesce G, Artaud F, Roze E, Degaey I, et al · · 2023 · cited 20× · PMID 36415953 · DOI 10.1093/brain/awac440
  5. Dietary Copper/Zinc Ratio and Type 2 Diabetes Risk in Women: The E3N Cohort Study.
    Laouali N, MacDonald CJ, MacDonald CJ, Shah S, et al · · 2021 · cited 19× · PMID 34444662 · DOI 10.3390/nu13082502
  6. Association of Physical Activity and Parkinson Disease in Women: Long-term Follow-up of the E3N Cohort Study.
    Portugal B, Artaud F, Degaey I, Roze E, et al · · 2023 · cited 16× · PMID 37197993 · DOI 10.1212/wnl.0000000000207424
  7. Application of two statistical approaches (Bayesian Kernel Machine Regression and Principal Component Regression) to assess breast cancer risk in association to exposure to mixtures of brominated flame retardants and per- and polyfluorinated alkylated substances in the E3N cohort
    Frenoy P, Perduca V, Cano-Sancho G, Antignac JP, et al · · 2022 · cited 15× · PMID 35216589 · DOI 10.1186/s12940-022-00840-4
  8. Use of systemic glucocorticoids and risk of breast cancer in a prospective cohort of postmenopausal women.
    Cairat M, Al Rahmoun M, Gunter MJ, Heudel PE, et al · · 2021 · cited 14× · PMID 34340701 · DOI 10.1186/s12916-021-02004-6

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

Other Institut National de la Santé Et de la Recherche Médicale, France trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03285230.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing